drugset
Drugs / Pfizer-BioNTech COVID-19 Vaccine 2023-2024
last change Feb 2025 re-read 3 minutes ago

Pfizer-BioNTech COVID-19 Vaccine 2023-2024

Vaccine

Developed for
disease related to solid organ transplantation
Investigated by
Johns Hopkins University · NYU Langone Health · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1

today NCT05077254 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05077254 Dec 2021 → Feb 2024 disease related to solid organ transplantation National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Pfizer-BioNTech COVID-19 Vaccine 2023-2024 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05077254 ↗
Modality Vaccine “mRNA based COVID-19 vaccine” NCT05077254 ↗
Route Intramuscular “One dose administered intramuscularly.” NCT05077254 ↗